CRISPR Therapeutic Off-Target Safety Assessment Planner

Scientists and regulatory affairs leads developing CRISPR-based therapeutics use this agent to design a comprehensive off-target analysis package that meets FDA and EMA expectations for IND-enabling studies, addressing both computational prediction and empirical confirmation of editing specificity.